{"preliminary_commentary":{"by_channel":{"x_thread":17,"podcast":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04513925\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"SKYSCRAPER-03","nct_id":"NCT04513925","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=skyscraper-03-nct04513925. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SKYSCRAPER-03","arms":[{"description":"Participants will receive atezolizumab administered intravenously (IV) on Day 1 of each 28-day cycle followed by tiragolumab administered IV on Day 1 of each 28-day cycle for a maximum of 13 cycles.","label":"Atezolizumab + Tiragolumab","type":"EXPERIMENTAL"},{"description":"Participants will receive durvalumab administered IV during each 28-day cycle for a maximum of 13 cycles.","label":"Durvalumab","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2025-07-31","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":{"count":829,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","otherNames":["Tecentriq; RO5541267"],"type":"DRUG"},{"name":"Tiragolumab","otherNames":["MTIG7192A; RO7092284"],"type":"DRUG"},{"name":"Durvalumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-03","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-05-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS)","timeFrame":"From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)"},{"measure":"PFS, as Assessed by an IRF in FAS","timeFrame":"From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)"}],"references":[],"start_date":{"date":"2020-08-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT04513925"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/skyscraper-03-nct04513925"}